Exbio — Research products — Antibodies — CD and related antigens — Anti-Hu CD38 PerCP-Cy™5.5

Anti-Hu CD38 PerCP-Cy™5.5

Regulatory status

RUO

Antigen

CD38

Clone

HB7

Format

PerCP-Cy™5.5

Reactivity

Human

Application

FC (QC tested)

Excitation laser

blue (488 nm)

Variant

100 tests

T9-915-T100

In stock

338.80 USD

Variant

100 tests

T9-915-T100

In stock

338.80 USD

Contact distributor

Product details

Description

Images

References

SDS download

Isotype

Mouse IgG1 kappa

Specificity

The mouse monoclonal antibody HB7 (HB-7) recognizes an extracellular epitope within amino acids 273-285 of human CD38, a 45 kDa type II transmembrane glycoprotein strongly expressed mainly on plasma cells and activated T and B lymphocytes; it is an antigenic marker of lymphoid cells. Its binding is blocked by daratumumab.

Workshop

HCDM III

Application

FC (QC tested)

Application details

Flow cytometry: The reagent is designed for analysis of human blood cells using 4 μl reagent / 100 μl of whole blood or 10⁶ cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests.

Reactivity

Human

Immunogen

BJAB cell line

Preparation

Purified antibody is conjugated with activated tandem dye of activated Peridinin-Chlorophyll Protein-Cyanine 5.5 (PerCP-Cy™5.5) under optimum conditions and unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.

Formulation

Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Storage and handling

Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.

The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

Cy™ and CyDye™ are registered trademarks of Cytiva.

Other names

ADPRC1, cADPr hydrolase 1, T10, NAD(+) nucleosidase, ADP-ribosyl cyclase 1

Antigen description

CD38 (NAD+ glycohydrolase) is a type II transmembrane glycoprotein able to induce activation, proliferation and differentiation of mature lymphocytes and mediate apoptosis of myeloid and lymphoid progenitor cells. Another role of CD38 is provided by enzymatic activity of its extracellular part. CD38 acts as NAD+ glycohydrolase converting NAD+ into ADP-ribose, as ADP-ribosyl cyclase producing cADPR and as cADPR hydrolase, thus affecting levels of calcium-mobilizing metabolites. ADPR produced by CD38 serves as an important second messenger of neutrophil and dendritic cell migration. CD38 belongs to markers of B cell subsets, leukemia, and a target of immunotherapy in myeloma treatment.

Entrez Gene ID 952

UniProt ID P28907

Flow cytometry surface staining pattern of human peripheral whole blood stained using anti-human CD38 (HB7) PerCP-Cy™5.5 antibody (concentration in sample 1.67 μg/ml).

Separation of human monocytes (red-filled) from CD38 negative lymphocytes (black-dashed) in flow cytometry analysis (surface staining) of human peripheral whole blood stained using anti-human CD38 (HB7) PerCP-Cy™5.5 antibody (concentration in sample 1.67 μg/ml).

General references:

Cakir-Kiefer C, Muller-Steffner H, Oppenheimer N, Schuber F: Kinetic competence of the cADP-ribose-CD38 complex as an intermediate in the CD38/NAD+ glycohydrolase-catalysed reactions: implication for CD38 signalling. Biochem J. 2001 Sep 1;358(Pt 2):399-406.
PubMed

Lund FE, Muller-Steffner H, Romero-Ramirez H, Moreno-García ME, Partida-Sánchez S, Makris M, Oppenheimer NJ, Santos-Argumedo L, Schuber F: CD38 induces apoptosis of a murine pro-B leukemic cell line by a tyrosine kinase-dependent but ADP-ribosyl cyclase- and NAD glycohydrolase-independent mechanism. Int Immunol. 2006 Jul;18(7):1029-42.
PubMed

Partida-Sanchez S, Gasser A, Fliegert R, Siebrands CC, Dammermann W, Shi G, Mousseau BJ, Sumoza-Toledo A, Bhagat H, Walseth TF, Guse AH, Lund FE. Chemotaxis of mouse bone marrow neutrophils and dendritic cells is controlled by adp-ribose, the major product generated by the CD38 enzyme reaction. J Immunol. 2007 Dec 1;179(11):7827-39.
PubMed

Product specific references:

Goldmacher VS, Bourret LA, Levine BA, Rasmussen RA, Pourshadi M, Lambert JM, Anderson KC: Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma. Blood 1994 Nov 1;84(9):3017-25.
PubMed

Zhao YJ, Zhu WJ, Wang XW, Zhang LH, Lee HC: Determinants of the membrane orientation of a calcium signaling enzyme CD38. Biochim Biophys Acta 2015 Sep;1853(9):2095-103.
PubMed

Berthelier V, Laboureau J, Boulla G, Schuber F, Deterre P: Probing ligand-induced conformational changes of human CD38. Eur J Biochem. 2000 May;267(10):3056-64.
PubMed

Li T, Qi S, Unger M, Hou YN, Deng QW, Liu J, Lam CM, Wang XW, Xin D, Zhang P, Koch-Nolte F, Hao Q, Zhang H, Lee HC, Zhao YJ: Immuno-targeting the multifunctional CD38 using nanobody. Sci Rep. 2016 Jun 2;6:27055.
PubMed

Ghose J, Viola D, Terrazas C, Caserta E, Troadec E, Khalife J, Gunes EG, Sanchez J, McDonald T, Marcucci G, Kaur B, Rosenzweig M, Keats J, Rosen S, Krishnan A, Satoskar AR, Hofmeister CC, Pichiorri F: Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. Oncoimmunology. 2018 Jul 23;7(10):e1486948.
PubMed

Ferrero E, Orciani M, Vacca P, Ortolan E, Crovella S, Titti F, Saccucci F, Malavasi F: Characterization and phylogenetic epitope mapping of CD38 ADPR cyclase in the cynomolgus macaque. BMC Immunol. 2004 Sep 21;5:21.
PubMed

Ratuszny D, Skripuletz T, Wegner F, Groß M, Falk C, Jacobs R, Ruschulte H, Stangel M, Sühs KW: Case report: Daratumumab in a patient with severe refractory anti-NMDA receptor encephalitis. Front Neurol. 2020 Dec 22;11:602102.
PubMed

Verhoeven D, Grinwis L, Marsman C, Jansen MH, van Leeuwen E, Kuijpers TW: B-cell targeting with anti-CD38 daratumumab: implications for differentiation and memory responses. Life Sci Alliance 2023 Jul 7;6(9):e202302214.
PubMed

Shrestha P, Astter Y, Davis DA, Zhou T, Yuan CM, Ramaswami R, Wang HW, Lurain K, Yarchoan R: Daratumumab induces cell-mediated cytotoxicity of primary effusion lymphoma and is active against refractory disease. Oncoimmunology 2023 Jan 7;12(1):2163784.
PubMed